MTOR and primary effusion lymphoma: Finally, considering the resistant nature of PEL to chemotherapy and our data demonstrating decreased expression and activity of ABC transporter proteins following JH295 treatment, we sought to determine whether JH295 administration could sensitize PEL to the mTOR inhibitor, rapamycin, an FDA-approved drug we previously reported for PEL (25).